ESMO’s annual European Lung Cancer Congress (ELCC) is a mainly educational event, taking place since it’s launch in April in Geneva.
Once back home, attendees will not have a load of practice-changing studies in their suitcase. They will rather have updated and checked their knowledge of recent evidence and best current practice in the field of lung cancer.
Looking back at the major advances in recent years – in particular due to advances in genetic profiling, imaging, and last but not least: immunotherapy – keeping up is an ever bigger challenge. Helping you to keep up is also our aim, providing you in this Medicom Report with some major summaries of ELCC events (acknowledging in advance that it cannot reflect the totality of the conference).
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Immunotherapy in SCLC: Trial Data Next Article
Treatment Options in Early NSCLC »
Table of Contents: ELCC 2019
Current Management of Early Stage NSCLC
Trial Data: Early Stage Lung Cancer
Immunotherapy in Stage 4 Lung Cancer
Trials: Immunotherapy in Stage 4 Lung Cancer
Implementation of Personalised Lung Cancer Care in Clinical Routine
Optimal Management of Brain Metastases in NSCLC
Small Cell Lung Cancer: New Targets
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.